Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Columbia • Supportive Care • NCI-CCC Breast Tumor Board Question • Bone health • Endocrinology
For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?
Answer from: Medical Oncologist at Academic Institution
In this case, I would be guided by the bone density (DXA) scan, if there is still osteoporosis or severe osteopenia, I would continue the BMA and repeat the DXA scan in one or two years. If the DXA shows improvement, I would discontinue the BMA, knowing that one can re-institute at a later date. Sev...
Sign in or Register to read more